notification_important

MHRA alerts & recalls

Review medicine recalls, record your assessment and keep track of follow-up actions.

All alerts

Read the alert. Keep a record of your response.

Create a free PharmData login to receive notifications. An active Starter or Pro subscription enables your pharmacy team to record assessments and follow-up actions.

Create a free account Sign in

2025-09-04 10:04:08 · Revision 1

Class 4 Medicines Defect Notification: Hikma Farmacêutica, Gemcitabine 2g/52.6ml concentrate for solution for infusion, EL(25)A/43

Hikma Farmacêutica (Portugal) S.A has informed the MHRA that the Patient Information Leaflet (PIL) contained within batch CB0033 of Gemcitabine 2g/52.6ml concentrate for solution for infusion does not contain the side effect…

Read full MHRA notice ↗

Source: Medicines and Healthcare products Regulatory Agency (MHRA). Read the full notice, including its required actions and deadlines, before recording your response.